

# Gerard London

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12192539/publications.pdf>

Version: 2024-02-01

44  
papers

2,565  
citations

304368

22  
h-index

214527

47  
g-index

48  
all docs

48  
docs citations

48  
times ranked

3526  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	1.4	14
2	Prognostic values of left ventricular mass index in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2021, 36, 665-672.	0.4	10
3	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.4	18
4	Hypertension in kidney transplantation: a consensus statement of the "hypertension and the kidney"™ working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.3	16
5	Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Journal of Hypertension, 2021, 39, 1444-1452.	0.3	4
6	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. Hypertension, 2021, 78, 983-995.	1.3	65
7	Survival with low- and high-flux dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1915-1923.	1.4	0
8	Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. Journal of Nephrology, 2020, 33, 1289-1300.	0.9	7
9	Protocol of the SPARTE Study: A Strategy for Preventing Cardiovascular and Renal Events based on ARTErial Stiffness. Artery Research, 2020, 26, 250-260.	0.3	10
10	Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 1542-1548.	0.4	21
11	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.4	23
12	Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.4	6
13	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. BMC Nephrology, 2019, 20, 81.	0.8	6
14	The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial. Kidney International, 2019, 95, 1505-1513.	2.6	65
15	Weak within-individual association of blood pressure and pulse wave velocity in hemodialysis is related to adverse outcomes. Journal of Hypertension, 2019, 37, 2200-2208.	0.3	10
16	Relative prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities in elderly haemodialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 848-858.	0.4	11
17	Pulse Wave Velocity and Prognosis in End-Stage Kidney Disease. Hypertension, 2018, 71, 1126-1132.	1.3	28
18	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.2	3

#	ARTICLE	IF	CITATIONS
19	Interaction Between Hypertension and Arterial Stiffness. <i>Hypertension</i> , 2018, 72, 796-805.	1.3	189
20	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. <i>Nefrologia</i> , 2018, 38, 520-527.	0.2	3
21	Long-term treatment with biosimilar epoetin- $\alpha$ (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. <i>Clinical Nephrology</i> , 2018, 89, 1-9.	0.4	7
22	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 344-358.	4.1	265
23	Ambulatory Pulse Wave Velocity Is a Stronger Predictor of Cardiovascular Events and All-Cause Mortality Than Office and Ambulatory Blood Pressure in Hemodialysis Patients. <i>Hypertension</i> , 2017, 70, 148-157.	1.3	96
24	Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure. <i>Kidney International</i> , 2017, 91, 704-710.	2.6	13
25	Optimizing hypertension management in renal transplantation: a call to action. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1959-1962.	0.4	14
26	Hypertension in Chronic Kidney Disease Part 1. <i>Hypertension</i> , 2016, 67, 1093-1101.	1.3	63
27	Hypertension in Chronic Kidney Disease Part 2. <i>Hypertension</i> , 2016, 67, 1102-1110.	1.3	86
28	Clinical imaging of vascular disease in chronic kidney disease. <i>International Urology and Nephrology</i> , 2016, 48, 827-837.	0.6	11
29	Con: Vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 352-357.	0.4	52
30	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 351-352.	0.4	3
31	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). <i>International Urology and Nephrology</i> , 2015, 47, 837-845.	0.6	3
32	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. <i>Hypertension</i> , 2015, 66, 3-9.	1.3	23
33	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1542-1551.	0.4	140
34	A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 490-496.	0.4	76
35	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. <i>Internal and Emergency Medicine</i> , 2013, 8, 389-399.	1.0	9
36	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1346-1359.	0.4	628

#	ARTICLE	IF	CITATIONS
37	Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622.	2.1	119
38	COSMOS: the dialysis scenario of CKDâ€“MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.4	79
39	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	2.6	136
40	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1725-1733.	2.2	49
41	The complexity of the cardioâ€“renal link: taxonomy, syndromes, and diseases. Kidney International Supplements, 2011, 1, 2-5.	4.6	24
42	Mineral and bone disease pattern in elderly haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 3062-3070.	0.4	37
43	Deferoxamine Test and Bone Disease in Dialysis Patients With Mild Aluminum Accumulation. American Journal of Kidney Diseases, 1989, 14, 124-130.	2.1	17
44	Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients. Kidney International, 1985, 27, 785-791.	2.6	57